Skip to main content

Table 5 Grade ≥ 3 hematological and non-hematological adverse events

From: Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis

ToxicityABCDEFGHIJK
(Grade ≥ 3)TaxCapBev + TaxBev + CapBev + ExmMot + TaxBev + Tax+CapBev + Cap+CycBev + Cap+VinBev + Tax+ExrBev + Tax+Tre
Total n3514714629185892357742955555
 n1/n2%n1/n2%n1/n2%n1/n2%n1/n2%n1/n2%n1/n2%n1/n2%n1/n2%n1/n2%n1/n2%
Hematologic  NANA          NANA      
 Anemia6/2312.6  22/9182.48/8510.90/580.0  5/3571.4    6/5510.9  
 Leukopenia10/2314.3  84/11457.33/8510.40/580.0  37/35710.4  32/29510.8    
 Neutropenia37/26214.1  267/136619.513/8511.50/580.0  64/35717.9  57/29519.311/5520.018/5532.7
Non-hematologic  NANA          NANA      
 Hypertension11/3513.1  133/14629.155/8516.525/5843.111/9212.039/35710.9  9/2953.12/553.618/5532.7
 Haemorrhage/bleeding2/2620.8  7/6241.13/2971.00/580.0  5/2462.0  3/2951.01/551.8  
 Thromboembolic events3/2621.1  17/7422.318/2976.11/581.7  28/3577.8  31/29510.5  5/559.1
 Neuropathy16/3205.0  156/144810.83/8510.40/580.010/9210.919/3575.3  11/2953.76/5510.920/5536.4
 Nausea/vomiting7/3202.2  28/9562.912/5742.10/580.018/9219.68/1555.2  19/2956.43/555.54/557.3
 Diarrhea9/3202.8  36/11643.129/5745.10/580.03/923.321/3575.9  10/2953.43/555.54/557.3
 Mucositis/stomatitis2/3200.6  25/7633.38/2972.70/580.01/921.120/3575.6  8/2952.78/5514.5  
 Edema6/2312.6  4/4201.0  0/580.0          2/553.6
 Proteinuria1/2620.4  14/5652.53/2971.0    18/2467.3  1/2950.34/557.3  
 Hepatobiliary disorders3/893.4  6/2132.8  4/586.97/927.6        0/550.0
 Hand-foot syndrome    4/6480.6157/85118.4    107/35730.0  43/29514.6    
 Fatigue20/3206.3  59/11645.110/5741.73/585.211/9212.022/3576.2  19/2956.48/5514.55/559.1
 Pain11/3203.4  22/9892.29/2773.22/583.49/929.84/2461.6    1/551.80/550.0
 Alopecia9/3202.8  13/6851.90/2770.00/580.00/920.0        4/557.3
 Infection10/3203.1  19/6153.127/2979.1  9/929.816/2666.0  37/29512.5    
  1. A = Tax, B = Cap, C = Bev + Tax, D = Bev + Cap, E = Bev + Exm, F = Mot + Tax, G = Bev + Tax+Cap, H = Bev + Cap+Cyc, I = Bev + Cap+Vin, J = Bev + Tax+ Eve, K = Bev + Tax+Tre
  2. Bev bevacizumab, Cap capecitabine, Tax taxanes, Vin vinorelbine, Cyc cyclophosphamide, Exm exemestane, Eve everolimus, Tre trebananib, Mot motesanib, NA not applicable, Total n number of all patients with regimens, n1/n2 the number of patients with adverse reactions / total enrolled patients
\